NASDAQ:BCAB

BioAtla (BCAB) Stock Forecast, Price & News

$3.64

-0.07 (-1.89%)

(As of 10:33 AM ET)

Compare

Today's Range: $3.64
▼
$3.76
50-Day Range: $2.46
▼
$3.87
52-Week Range: $2.23
▼
$12.15

Volume: 56,597 shs
Average Volume: 634,713 shs
Market Capitalization: $173.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.67

BioAtla MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 322.3% Upside
$15.67 Price Target
Short Interest: Healthy
7.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$148,776 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.48) to ($2.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

145th out of 981 stocks

Biological Products, Except Diagnostic Industry

21st out of 165 stocks

3.4

Analyst's Opinion

Consensus Rating
BioAtla has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.67, BioAtla has a forecasted upside of 322.3% from its current price of $3.71.
Amount of Analyst Coverage
BioAtla has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
7.53% of the outstanding shares of BioAtla have been sold short.
Short Interest Ratio / Days to Cover
BioAtla has a short interest ratio ("days to cover") of 7.2.
Change versus previous month
Short interest in BioAtla has recently decreased by 5.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BioAtla does not currently pay a dividend.
Dividend Growth
BioAtla does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCAB.

2.9

News and Social Media Coverage

News Sentiment
BioAtla has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BioAtla this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.
MarketBeat Follows
3 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,776.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.38% of the stock of BioAtla is held by insiders.
Percentage Held by Institutions
66.15% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BioAtla are expected to grow in the coming year, from ($2.48) to ($2.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioAtla is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioAtla is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioAtla has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioAtla (NASDAQ:BCAB) Stock

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

BCAB Stock News Headlines

June 1, 2023 | americanbankingnews.com

Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Declines By 5.0%

May 31, 2023 | finance.yahoo.com

BioAtla to Participate in the Jefferies Healthcare Conference

June 8, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 26, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Average PT from Analysts

May 19, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for BioAtla, Inc. (NASDAQ:BCAB) Issued By HC Wainwright

May 16, 2023 | msn.com

JMP Securities Reiterates BioAtla (BCAB) Outperform Recommendation

May 16, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Expected to Post Q1 2024 Earnings of ($0.61) Per Share

May 15, 2023 | markets.businessinsider.com

Where BioAtla Stands With Analysts

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 15, 2023 | msn.com

HC Wainwright & Co. Reiterates BioAtla (BCAB) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)

May 15, 2023 | markets.businessinsider.com

BioAtla (BCAB) Receives a Buy from JMP Securities

May 13, 2023 | msn.com

EF Hutton Reiterates BioAtla (BCAB) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

BioAtla (BCAB) Receives a Buy from BTIG

May 11, 2023 | finance.yahoo.com

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 11, 2023 | investing.com

Bioatla (BCAB) Earnings Dates & Reports

May 8, 2023 | finance.yahoo.com

BioAtla to Participate in the JMP Securities Life Sciences Conference

May 4, 2023 | finance.yahoo.com

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

May 1, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Average Price Target from Analysts

April 29, 2023 | finance.yahoo.com

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

April 19, 2023 | msn.com

EF Hutton Maintains BioAtla (BCAB) Buy Recommendation

April 19, 2023 | americanbankingnews.com

BioAtla (NASDAQ:BCAB) Given Buy Rating at EF Hutton Acquisition Co. I

April 8, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Receives $15.67 Consensus Target Price from Analysts

April 3, 2023 | americanbankingnews.com

BioAtla (NASDAQ:BCAB) Price Target Lowered to $19.00 at JPMorgan Chase & Co.

April 1, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) CEO Purchases $100,776.00 in Stock

March 30, 2023 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Insider Christian Vasquez Acquires 20,000 Shares

March 30, 2023 | americanbankingnews.com

BioAtla (NASDAQ:BCAB) Price Target Cut to $13.00

See More Headlines

BCAB Price History

30 days | 90 days | 365 days | Advanced Chart

BCAB Company Calendar

Last Earnings: 3/23/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCAB
CUSIP: N/A
CIK: 1826892
Web: www.bioatla.com
Phone: 858-558-0708
Fax: N/A
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.67
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +322.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -68.09%
Return on Assets: -52.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.61
Quick Ratio: 7.61

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 707.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.79 per share
Price / Book: 0.98

Miscellaneous

Outstanding Shares: 47,670,000
Free Float: 43,673,000
Market Cap: $176.86 million
Optionable: Not Optionable
Beta: 0.27

Key Executives

Dr. Jay M. Short Ph.D. (Age 65)
Co-Founder, CEO & Chairman
Comp: $1.02M

Mr. Scott Andrew Smith (Age 61)
Pres & Director
Comp: $798.89k

Mr. Richard A. Waldron (Age 69)
Chief Financial Officer
Comp: $593.51k

Dr. Eric L. Sievers M.D. (Age 59)
Chief Medical Officer
Comp: $552.62k

Mr. Christian Vasquez (Age 48)
VP of Fin., Corp. Controller & Sec.
Comp: $345.88k

Mr. Philippe Martin (Age 47)
Chief Clinical Devel. & Operations

Lisa M. Pelton
Accounting Mang.

Ms. Susie Melody
Sr. VP of HR

Dr. Cathy Chang Ph.D.
Sr. VP of R&D

Ms. Monica Sullivan
Sr. VP of Intellectual Property & Contracts

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCAB Stock - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings or view top-rated stocks.
What is BioAtla's stock price forecast for 2023?: 6 Wall Street research analysts have issued 12 month price targets for BioAtla's stock. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they predict the company's share price to reach $15.67 in the next twelve months. This suggests a possible upside of 322.3% from the stock's current price.
View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts.
How have BCAB shares performed in 2023?: BioAtla's stock was trading at $8.25 at the start of the year. Since then, BCAB stock has decreased by 55.0% and is now trading at $3.71.
View the best growth stocks for 2023 here.
Are investors shorting BioAtla?: BioAtla saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 3,590,000 shares, a decrease of 5.0% from the April 30th total of 3,780,000 shares. Based on an average daily trading volume, of 499,900 shares, the days-to-cover ratio is currently 7.2 days.
View BioAtla's Short Interest.
When is BioAtla's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BCAB earnings forecast.
How were BioAtla's earnings last quarter?: BioAtla, Inc. (NASDAQ:BCAB) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.11.

What ETFs hold BioAtla's stock?: ETFs with the largest weight of BioAtla (NASDAQ:BCAB) stock in their portfolio include Formidable ETF (FORH).ALPS Medical Breakthroughs ETF (SBIO).
When did BioAtla IPO?: (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO.
What is BioAtla's stock symbol?: BioAtla trades on the NASDAQ under the ticker symbol "BCAB."
Who are BioAtla's major shareholders?: BioAtla's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam S.C.A. (3.29%), Wasatch Advisors LP (2.66%), BlackRock Inc. (2.07%), Deutsche Bank AG (1.45%), Vontobel Holding Ltd. (1.16%) and Sectoral Asset Management Inc. (1.14%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn.
View institutional ownership trends.
How do I buy shares of BioAtla?: Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioAtla's stock price today?: One share of BCAB stock can currently be purchased for approximately $3.71.
How much money does BioAtla make?: BioAtla (NASDAQ:BCAB) has a market capitalization of $176.86 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.
How can I contact BioAtla?: The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com.

This page (NASDAQ:BCAB) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioAtla (BCAB) Stock Forecast, Price & News

BioAtla MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioAtla (NASDAQ:BCAB) Stock

BCAB Stock News Headlines

BCAB Price History

BCAB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BCAB Stock - Frequently Asked Questions

Overall MarketRank^™